Table 2 Baseline characteristics of the study population

Age (year)

60.5 (8.7)

59.3 (8.7)

62.3 (9.5)

59.9 (7.7)

0.137^a

Sex, men, n (%)

99 (73.3)

31 (67.4)

34 (75.6)

34 (77.3)

0.524^b

Body mass index (kg/m²)

25.6 (2.7)

26.4 (2.8)

25.1 (2.6)

25.4 (2.8)

0.033^a

Baseline blood pressure, mmHg

 Systolic

152.8 (9.5)

152.5 (9.9)

151.3 (9.0)

154.7 (9.5)

0.157^a

 Diastolic

89.4 (9.1)

89.4 (8.3)

85.8 (9.3)

93.1 (8.5)

0.001^a

Baseline Pulse Rate (beats/min)

75.2 (12.1)

76.4 (13.1)

73.0 (10.9)

76.2 (12.3)

0.441^a

Baseline LDL-C (mg/dL)

165.7 (34.6)

171.3 (36.0)

164.1 (39.6)

161.4 (26.7)

0.294^a

Smoking, n (%)

 Current Smoker

37 (27.4)

14 (30.4)

12 (26.7)

11 (25.0)

0.933^b

 Non-smoker

57 (42.2)

17 (37.0)

2 0 (44.4)

20 (45.5)

 Ex-smoker

41 (30.4)

15 (32.6)

13 (28.9)

13 (29.6)

Drinking, n (%)

 Current drinker

83 (61.5)

30 (65.2)

27 (60.0)

26 (59.1)

0.811^b

 Non-drinker

52 (38.5)

16 (34.8)

18 (40.0)

18 (40.9)

Medication history of cardiovascular system, n (%)

 Lipid modifying agents

93 (68.9)

31 (67.4)

34 (75.6)

28 (63.6)

 ACE inhibitors or ARBs

81 (60.0)

28 (60.9)

29 (64.4)

24 (54.6)

 Calcium channel blockers

38 (28.2)

9 (19.6)

13 (28.9)

16 (36.4)

 Beta blockers

10 (7.4)

1 (2.2)

4 (8.9)

5 (11.4)

 Cardiac drugs

7 (5.2)

-

5 (11.1)

2 (4.6)

 Diuretics

5 (3.7)

1 (2.2)

2 (4.4)

2 (4.6)

 Peripheral vasodilators

4 (3.0)

1 (2.2)

3 (6.7)

-

 Vasoprotectives

1 (0.7)

-

-

1 (2.3)

Medical history, n (%)

 Diabetes mellitus

33 (24.4)

8 (17.4)

16 (35.6)

9 (20.5)

 Angina pectoris

6 (4.4)

1 (2.2)

2 (4.4)

3 (6.8)